Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)
Launched by H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE · Mar 6, 2024
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
The BASH OPC trial is studying a new way to detect a specific type of throat cancer that is linked to the human papillomavirus (HPV). Researchers are testing a special test that looks for HPV DNA and changes in certain genes to see if it can accurately identify early cases of oropharyngeal cancer (OPC) before any treatment is given. They will compare results from 100 patients with early-stage cancer, 100 with late-stage cancer, and 200 healthy individuals who are similar in age, sex, race, and tobacco use, all collected from two major cancer centers.
To participate in this trial, you need to be at least 18 years old and have a newly diagnosed, confirmed case of squamous cell carcinoma of the oropharynx that hasn't been treated yet. You should also not have any history of head and neck cancers or HPV-related cancers. If you join the study, you'll provide consent to participate and help researchers learn more about this cancer detection method. This trial is currently recruiting participants and aims to improve early detection, which is important for better treatment outcomes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Cases:
- • Aged at least 18 years
- • Newly diagnosed primary tumor, histologically confirmed squamous cell carcinoma of the oropharynx (stages I-IV)
- • Has not received treatment (surgery, chemotherapy, radiation, or immunotherapy) within the previous four weeks
- • Provided written informed consent under Moffitt Cancer Center (MCC) 17716 biomarker/biobanking study or is identified and enrolled at the University of Pittsburgh Medical Center Hillman Cancer Center
- • Aged at least 35 years
- • Have no previous diagnosis of HNC or HPV-related cancer
- • Fully understands study procedures
- • Voluntarily agrees to participate by giving written informed consent under Moffitt Cancer Center (MCC) 17716 biomarker/biobanking study or is enrolled at the University of Pittsburgh Medical Center Hillman Cancer Center
- Exclusion Criteria:
- • Not meeting all of the above inclusion criteria for either the case or control group
About H. Lee Moffitt Cancer Center And Research Institute
H. Lee Moffitt Cancer Center and Research Institute is a leading institution dedicated to cancer research, treatment, and education, recognized for its commitment to advancing cancer care through innovative clinical trials and groundbreaking research. As a National Cancer Institute-designated Comprehensive Cancer Center, Moffitt integrates cutting-edge science with patient-centered care, offering a multidisciplinary approach to cancer treatment. The center is at the forefront of developing novel therapies and improving outcomes for patients, emphasizing collaboration between researchers and clinicians to translate scientific discoveries into effective treatments. Through its extensive clinical trial programs, Moffitt aims to enhance the understanding of cancer biology and provide patients with access to the latest therapies and interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tampa, Florida, United States
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Anna Giuliano, PhD
Principal Investigator
Moffitt Cancer Center
Antonio Amelio, PhD
Principal Investigator
Moffitt Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported